EUVIMEDEUVIMED entdecken
Crossref

Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management

Mrinal M Patnaik iD, Ayalew Tefferi iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Mrinal M Patnaik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Atypical chronic myeloid leukemia (aCML) and myelodysplastic/myeloproliferative (MDS/MPN) neoplasms, not otherwise specified (NOS), are MDS/MPN overlap neoplasms characterized by leukocytosis, in the absence of monocytosis and eosinophilia, with 67 years, hemoglobin 2 points) groups, with median survivals of 18 and 7 months, respectively. MDS/MPN‐NOS patients have traditionally been risk stratified using MDS risk models such as IPSS and IPSS‐R. Treatment Leukocytosis and anemia are managed like lower risk MPN and MDS. DNMT inhibitors have been used in both entities with suboptimal response rates. Allogeneic stem cell transplant remains the only curative strategy but is associated with high morbidity and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia, Myelomonocytic, ChronicThrombocytosisHumansAgedLeukocytosisMutationRisk Assessment

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Mrinal M Patnaik, Ayalew Tefferi

Zitieren

APA

Patnaik, M. M., & Tefferi, A. (2023). Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology. https://doi.org/10.1002/ajh.26828

Vancouver

Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2023. doi:10.1002/ajh.26828

BibTeX
@article{Patnaik2023,
  author = {Patnaik, Mrinal M and Tefferi, Ayalew},
  title = {Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26828}
}
Kostenlos starten →